Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, Shapiro RL, Berman RS, Berner N, Shao Y, Manches O, Pan L, Venhaus RR, Hoffman EW, Jungbluth A, Gnjatic S, Old L, Pavlick AC, Bhardwaj N.
Adams S, et al. Among authors: shao y.
J Immunol. 2008 Jul 1;181(1):776-84. doi: 10.4049/jimmunol.181.1.776.
J Immunol. 2008.
PMID: 18566444
Free PMC article.
Clinical Trial.